Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 10/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20125086 | 0.83 | CYP1A2 (0.46) | EIF2AK4TGFBR1PRMT5WDR77 | |
| SCHEMBL15829283 | 0.82 | EIF2AK4 (0.46) | EIF2AK4TGFBR1 | |
| SCHEMBL22955952 | 0.72 | RXRA (0.31) | EIF2AK4TGFBR1JAK2JAK3JAK1 | |
| SCHEMBL22521532 | 0.72 | TGFBR1 (0.41) | EIF2AK4TGFBR1RXRA | |
| SCHEMBL14773395 | 0.70 | FLT3 (0.54) | TGFBR1JAK2JAK3JAK1 | |
| SCHEMBL13976120 | 0.69 | LMNA (0.39) | EIF2AK4TGFBR1JAK2JAK3JAK1 | |
| SCHEMBL11994463 | 0.69 | HDAC3 (0.53) | TDP1 | |
| SCHEMBL22212202 | 0.68 | FLT1 (0.36) | EIF2AK4TGFBR1RXRA | |
| SCHEMBL23511269 | 0.67 | DGAT1 (0.40) | — | |
| SCHEMBL22944713 | 0.67 | NPC1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | EIF2AK4 2446/4885TGFBR1 4462/4885JAK2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.